Huntsman

Heightened Global Regulations And Rising Input Costs Will Stall Recovery

AnalystLowTarget

Not Invested

Consensus Narrative from 13 Analysts

Published

27 Aug 25

Updated

27 Aug 25

AnalystLowTarget's Fair Value

US$9.00

21.0% overvalued

27 Aug

US$10.89

-50.4%

6.9%

-50.4%

6.9%

Author's Valuation

US$9.0

21.0% overvalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

US$9.0

21.0% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

3.15%

Chemicals revenue growth rate

0.37%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

9.87%

Calculation

US$119.95m

Earnings '28

17.53x

PE Ratio '28

US$2.10b

Market Cap '28

US$2.10b

Market Cap '28

176.05m

No. shares '28

US$11.94

Share Price '28

US$11.94 Share Price '28

Discounted to 2025 @ 9.90% p.a.

US$9.00

Fair Value '25